FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 01:10:17 27/06/2024 am IST | ||
| 0.18 EUR | 0.00% |
|
| Current month | -35.71% | ||
| 1 month | -35.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 0.18 | 0.00% |
| 25/24/25 | 0.18 | 0.00% |
| 24/24/24 | 0.18 | -5.26% |
| 21/24/21 | 0.19 | -5.00% |
| 20/24/20 | 0.2 | -4.76% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU0N1N |
| ISIN | DE000SU0N1N0 |
| Date issued | 13/10/2023 |
| Strike | 365.6 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.27 € |
|---|---|
| Lowest since issue | 0.15 € |
| Spread | 0.01 € |
| Spread % | 5.26% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
